Therefore, clinicians may contemplate a lower threshold to consider thromboprophylaxis in patients with NSCLC and either ALK or ROS1 rearrangement who otherwise have traditional risk scores in the intermediate risk range. Here, ALK is linked to non-small cell lung carcinoma.